All Oncology News

The FDA has approved ramucirumab (Cyramza) monotherapy for patients with hepatocellular carcinoma who have an alpha fetoprotein of ≥400 ng/ML and have been previously treated with sorafenib.

Pei-Chun McGregor, MD, discusses where future research with androgen deprivation therapy-associated adverse events is headed, and called for multidisciplinary care for patients receiving this approach.

The combination of nivolumab plus radiation therapy compared with temozolomide did not improve overall survival in patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma multiforme, missing the coprimary endpoint of the phase III CheckMate-498 trial.

Atish D. Choudhury, MD, PhD, details the advances in metastatic prostate cancer in light of updated analyses from several clinical trials and forthcoming research in the field.

This month, OncLive® officially launched the OncLive® Community, a social network designed specifically for healthcare professionals working in the field of oncology.

Joanne Mortimer, MD, discusses key facets of treatment for patients with early and metastatic HER2-positive breast cancer.

Daphne B. Stewart, MD, highlights the pivotal trials evaluating CDK4/6 inhibitors and what unanswered questions remain with this class of agents.

Guru Sonpavde, MD, discusses the current use of immunotherapy and the numerous strategies in development in bladder cancer.

Lyndsey Runaas, MD, discusses the newfound outlook for patients with FLT3- and IDH1/2-mutant acute myeloid leukemia given recent regulatory approvals and trial data.

The antibody-drug conjugate [fam-] trastuzumab deruxtecan (DS-8201) demonstrated encouraging responses in patients with unresectable and/or metastatic HER2-positive breast cancer that has been previously treated with ado-trastuzumab emtansine, according to topline findings from the phase II DESTINY-BreastO1 study.

A vaccine targeting GUCY2C, a commonly overexpressed protein in patients with early-stage colorectal cancer, induced antibody and T-cell responses toward the specified target and demonstrated an acceptable safety profile in this patient population

Nirav N. Shah, MD, discusses the promise of CAR T-cell therapy in hematologic malignancies and highlights recent research exploring sequential CAR-T therapies, armored CAR T cells, as well as other novel approaches.

Sameem Abedin, MD, discusses the recent encouraging data in chronic lymphocytic leukemia with venetoclax, duvelisib, and acalabrutinib.

Laura Kruper, MD, MS, discusses outstanding questions within the context of the current management of the axilla.

John Theurer Cancer Center announced that it has been approved by the National Cancer Institute to become a member of the NCI-designated Georgetown Lombardi Comprehensive Cancer Center Consortium.

Richard (Rick) JaeBong Lee, MD, PhD, discusses the differences between second-generation targeted antiandrogens and highlights potential factors to consider in terms of selection.

The FDA has granted a fast track designation to the CCR5 antagonist leronlimab for use in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer.

Acalabrutinib improved progression-free survival compared with rituximab plus either idelalisib or bendamustine in previously treated patients with chronic lymphocytic leukemia, according to findings from the phase III ASCEND trial.

Parameswaran Hari, MD, MRCP, discusses the rapidly evolving paradigm of myeloma with a focus on the latest updates in the frontline setting.

Sayeh Lavasani, MD, MS, discusses the application of gene assays in the management of patients with hormone receptor-positive breast cancer, as well as ongoing research in this space.

Scott Kopetz, MD, PhD, FACP, explains the biologic difference between left- and right-sided colorectal cancer and highlights recent research on tumor sidedness and its impact on clinical practice.

Saurabh Chhabra, MD, MS, highlights emerging agents in the field of relapsed/refractory myeloma that have oncologists optimistic for the future.

Laura Michaelis, MD, highlights the many ruxolitinib combinations under investigation and provided insight into the role of interferon in myeloproliferative neoplasms.

Yuan Yuan, MD, PhD, discusses how treating physicians are optimizing novel agents for patients with metastatic triple-negative breast cancer.

David J. Einstein, MD, discusses newer imaging techniques and overall progress in the treatment of patients with nonmetastatic hormone-sensitive prostate cancer.

The antibody-drug conjugate mirvetuximab soravtansine demonstrated a favorable benefit-risk profile in a prespecified subset of patients with folate receptor alpha–positive ovarian cancer, following a comprehensive analysis of the phase III FORWARD I trial.

The FDA has approved ado-trastuzumab emtansine (T-DM1; Kadcyla) for use as an adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant trastuzumab and chemotherapy.

Alfredo Addeo, MD, discusses the uniqueness of the 1-day Lung Cancer Summit and recent therapeutic advancements that have occurred in the lung cancer space.

The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer, now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.

In an effort to improve outcomes for intermediate- or poor-risk patients with renal cell carcinoma, the phase III COSMIC-313 trial is being initiated, which will evaluate cabozantinib (Cabometyx) in combination with nivolumab and ipilimumab in patients with previously untreated advanced disease.